Methotrexate for inflammatory bowel disease: time for reconsideration

Ole Haagen Nielsen; Mark Andrew Ainsworth; Casper Steenholdt

doi:10.1080/17474124.2019.1596797

Methotrexate for inflammatory bowel disease: time for reconsideration

Ole Haagen Nielsen, Mark Andrew Ainsworth, Casper Steenholdt

Afdeling for Mave-, Tarm- og Leversygdomme HGH

9 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Expert review of gastroenterology & hepatology
Vol/bind	13
Udgave nummer	5
Sider (fra-til)	407-409
Antal sider	3
ISSN	1747-4124
DOI	https://doi.org/10.1080/17474124.2019.1596797
Status	Udgivet - maj 2019

Adgang til dokumentet

10.1080/17474124.2019.1596797

Citationsformater

@article{0d5057e93de44bba9ec2c17a280fccd0,

title = "Methotrexate for inflammatory bowel disease: time for reconsideration",

keywords = "Anti-Inflammatory Agents/adverse effects, Biological Products/therapeutic use, Clinical Decision-Making, Colitis, Ulcerative/diagnosis, Combined Modality Therapy, Crohn Disease/diagnosis, Evidence-Based Medicine, Gastrointestinal Agents/adverse effects, Humans, Methotrexate/adverse effects, Patient Selection, Remission Induction, Treatment Outcome",

author = "Nielsen, {Ole Haagen} and Ainsworth, {Mark Andrew} and Casper Steenholdt",

year = "2019",

month = may,

doi = "10.1080/17474124.2019.1596797",

language = "English",

volume = "13",

pages = "407--409",

journal = "Expert review of gastroenterology & hepatology",

issn = "1747-4124",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Methotrexate for inflammatory bowel disease

T2 - time for reconsideration

AU - Nielsen, Ole Haagen

AU - Ainsworth, Mark Andrew

AU - Steenholdt, Casper

PY - 2019/5

Y1 - 2019/5

KW - Anti-Inflammatory Agents/adverse effects

KW - Biological Products/therapeutic use

KW - Clinical Decision-Making

KW - Colitis, Ulcerative/diagnosis

KW - Combined Modality Therapy

KW - Crohn Disease/diagnosis

KW - Evidence-Based Medicine

KW - Gastrointestinal Agents/adverse effects

KW - Humans

KW - Methotrexate/adverse effects

KW - Patient Selection

KW - Remission Induction

KW - Treatment Outcome

U2 - 10.1080/17474124.2019.1596797

DO - 10.1080/17474124.2019.1596797

M3 - Journal article

C2 - 30895827

SN - 1747-4124

VL - 13

SP - 407

EP - 409

JO - Expert review of gastroenterology & hepatology

JF - Expert review of gastroenterology & hepatology

IS - 5

ER -